GT
ABEO icon

Glenmede Trust’s Abeona Therapeutics ABEO Stock Holding History

Glenmede Trust’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4
Closed – – 2997
2019
Q2 		$0 Hold
4
– – ﹤0.01% 3053
2019
Q1 		$0 Sell
4
-8
-67% -$1.43K ﹤0.01% 3045
2018
Q4 		$2 Buy
+12
New +$2.62K ﹤0.01% 2743
2017
Q3 		– Sell
-80
Closed -$10K – 2724
2017
Q2 		$10K Hold
80
– – ﹤0.01% 2115
2017
Q1 		$10K Buy
+80
New +$10.3K ﹤0.01% 2115

Other funds holding ABEO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Glenmede Trust's ABEO Position: Q3 2019 in Review

Glenmede Trust sold out of Abeona Therapeutics (ABEO) in Q3 2019, closing a stake of 4 shares.

Glenmede Trust first reported a position in ABEO in Q1 2017 and held it in 5 quarters. The position peaked at $10K in Q2 2017. 79 funds tracked by Wall St. Rank hold ABEO as of Q3 2019.

  • Glenmede Trust reported no remaining Abeona Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Glenmede Trust sold 4 Abeona Therapeutics shares in Q3 2019.
  • Glenmede Trust first reported a position in Abeona Therapeutics in Q1 2017 and held it in 5 quarters.
  • Glenmede Trust's Abeona Therapeutics position peaked at $10K in Q2 2017.
  • 79 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2019.

Based on Glenmede Trust's 13F filing for Q3 2019, filed 14 Nov 2019.